Systemic therapy and targeted agents in advanced esophageal cancer

Mark A. Lewis, Harry H Yoon

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter summarizes recent progress in the treatment of patients with advanced adenocarcinoma of the esophageal and gastroesophageal junction, with a focus on the clinical development of systemic targeted agents. To date, monoclonal antibodies targeting the human epidermal growth factor receptor (HER) 2 (trastuzumab) and tumor-related angiogenesis (ramucirumab) have been shown to improve overall survival in Phase 3 trials of esophagogastric adenocarcinoma, whereas a lack of meaningful efficacy has been demonstrated by epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies (cetuximab, panitumumab) and small molecule inhibitors (gefitinib). Benefit from the dual EGFR/HER2-targeted tyrosine kinase inhibitor, lapatinib, appears to be limited, although responsive subpopulations may be identified. Success in further development of anti-cancer therapies in advanced disease will likely rely on focusing patient enrollment on those with actionable molecular targets.

Original languageEnglish (US)
Title of host publicationEsophageal Cancer and Barrett's Esophagus
PublisherWiley Blackwell
Pages251-264
Number of pages14
ISBN (Electronic)9781118655153
ISBN (Print)9781118655207
DOIs
StatePublished - Dec 12 2015

Fingerprint

Esophageal Neoplasms
Epidermal Growth Factor Receptor
Adenocarcinoma
Monoclonal Antibodies
Esophagogastric Junction
Protein-Tyrosine Kinases
Neoplasms
Survival
Therapeutics
human ERBB2 protein
gefitinib
ramucirumab
panitumumab
lapatinib
Cetuximab
Trastuzumab

Keywords

  • EGFR
  • Esophageal adenocarcinoma
  • Esophageal cancer
  • Gastroesophageal junction adenocarcinoma
  • Gastroesophageal junction cancer
  • HER2
  • Ramucirumab
  • Targeted therapy
  • Trastuzumab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lewis, M. A., & Yoon, H. H. (2015). Systemic therapy and targeted agents in advanced esophageal cancer. In Esophageal Cancer and Barrett's Esophagus (pp. 251-264). Wiley Blackwell. https://doi.org/10.1002/9781118655153.ch26

Systemic therapy and targeted agents in advanced esophageal cancer. / Lewis, Mark A.; Yoon, Harry H.

Esophageal Cancer and Barrett's Esophagus. Wiley Blackwell, 2015. p. 251-264.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lewis, MA & Yoon, HH 2015, Systemic therapy and targeted agents in advanced esophageal cancer. in Esophageal Cancer and Barrett's Esophagus. Wiley Blackwell, pp. 251-264. https://doi.org/10.1002/9781118655153.ch26
Lewis MA, Yoon HH. Systemic therapy and targeted agents in advanced esophageal cancer. In Esophageal Cancer and Barrett's Esophagus. Wiley Blackwell. 2015. p. 251-264 https://doi.org/10.1002/9781118655153.ch26
Lewis, Mark A. ; Yoon, Harry H. / Systemic therapy and targeted agents in advanced esophageal cancer. Esophageal Cancer and Barrett's Esophagus. Wiley Blackwell, 2015. pp. 251-264
@inbook{5c6b2f60f2144be7a7b817de1ac27d60,
title = "Systemic therapy and targeted agents in advanced esophageal cancer",
abstract = "This chapter summarizes recent progress in the treatment of patients with advanced adenocarcinoma of the esophageal and gastroesophageal junction, with a focus on the clinical development of systemic targeted agents. To date, monoclonal antibodies targeting the human epidermal growth factor receptor (HER) 2 (trastuzumab) and tumor-related angiogenesis (ramucirumab) have been shown to improve overall survival in Phase 3 trials of esophagogastric adenocarcinoma, whereas a lack of meaningful efficacy has been demonstrated by epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies (cetuximab, panitumumab) and small molecule inhibitors (gefitinib). Benefit from the dual EGFR/HER2-targeted tyrosine kinase inhibitor, lapatinib, appears to be limited, although responsive subpopulations may be identified. Success in further development of anti-cancer therapies in advanced disease will likely rely on focusing patient enrollment on those with actionable molecular targets.",
keywords = "EGFR, Esophageal adenocarcinoma, Esophageal cancer, Gastroesophageal junction adenocarcinoma, Gastroesophageal junction cancer, HER2, Ramucirumab, Targeted therapy, Trastuzumab",
author = "Lewis, {Mark A.} and Yoon, {Harry H}",
year = "2015",
month = "12",
day = "12",
doi = "10.1002/9781118655153.ch26",
language = "English (US)",
isbn = "9781118655207",
pages = "251--264",
booktitle = "Esophageal Cancer and Barrett's Esophagus",
publisher = "Wiley Blackwell",

}

TY - CHAP

T1 - Systemic therapy and targeted agents in advanced esophageal cancer

AU - Lewis, Mark A.

AU - Yoon, Harry H

PY - 2015/12/12

Y1 - 2015/12/12

N2 - This chapter summarizes recent progress in the treatment of patients with advanced adenocarcinoma of the esophageal and gastroesophageal junction, with a focus on the clinical development of systemic targeted agents. To date, monoclonal antibodies targeting the human epidermal growth factor receptor (HER) 2 (trastuzumab) and tumor-related angiogenesis (ramucirumab) have been shown to improve overall survival in Phase 3 trials of esophagogastric adenocarcinoma, whereas a lack of meaningful efficacy has been demonstrated by epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies (cetuximab, panitumumab) and small molecule inhibitors (gefitinib). Benefit from the dual EGFR/HER2-targeted tyrosine kinase inhibitor, lapatinib, appears to be limited, although responsive subpopulations may be identified. Success in further development of anti-cancer therapies in advanced disease will likely rely on focusing patient enrollment on those with actionable molecular targets.

AB - This chapter summarizes recent progress in the treatment of patients with advanced adenocarcinoma of the esophageal and gastroesophageal junction, with a focus on the clinical development of systemic targeted agents. To date, monoclonal antibodies targeting the human epidermal growth factor receptor (HER) 2 (trastuzumab) and tumor-related angiogenesis (ramucirumab) have been shown to improve overall survival in Phase 3 trials of esophagogastric adenocarcinoma, whereas a lack of meaningful efficacy has been demonstrated by epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies (cetuximab, panitumumab) and small molecule inhibitors (gefitinib). Benefit from the dual EGFR/HER2-targeted tyrosine kinase inhibitor, lapatinib, appears to be limited, although responsive subpopulations may be identified. Success in further development of anti-cancer therapies in advanced disease will likely rely on focusing patient enrollment on those with actionable molecular targets.

KW - EGFR

KW - Esophageal adenocarcinoma

KW - Esophageal cancer

KW - Gastroesophageal junction adenocarcinoma

KW - Gastroesophageal junction cancer

KW - HER2

KW - Ramucirumab

KW - Targeted therapy

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84976871759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976871759&partnerID=8YFLogxK

U2 - 10.1002/9781118655153.ch26

DO - 10.1002/9781118655153.ch26

M3 - Chapter

SN - 9781118655207

SP - 251

EP - 264

BT - Esophageal Cancer and Barrett's Esophagus

PB - Wiley Blackwell

ER -